BioXcel Therapeutics, Inc.
BTAI
$1.71
-$0.03-1.72%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 64.20% | 83.25% | 131.50% | 202.24% | 268.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.20% | 83.25% | 131.50% | 202.24% | 268.00% |
| Cost of Revenue | 70.02% | 264.39% | 2,387.27% | 4,493.10% | 6,205.00% |
| Gross Profit | 2.52% | -63.56% | 5.29% | -23.19% | -66.48% |
| SG&A Expenses | -58.65% | -57.66% | -35.01% | -8.30% | 20.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -60.31% | -62.11% | -45.55% | -20.90% | 5.61% |
| Operating Income | 61.34% | 63.01% | 46.49% | 21.62% | -4.99% |
| Income Before Tax | 66.71% | 66.45% | 46.86% | 18.19% | -8.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 66.71% | 66.45% | 46.86% | 18.19% | -8.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 66.71% | 66.45% | 46.86% | 18.19% | -8.02% |
| EBIT | 61.34% | 63.01% | 46.49% | 21.62% | -4.99% |
| EBITDA | 61.45% | 63.10% | 46.56% | 21.65% | -5.01% |
| EPS Basic | 73.71% | 70.75% | 50.09% | 21.90% | -4.12% |
| Normalized Basic EPS | 74.06% | 70.97% | 52.39% | 24.05% | -1.72% |
| EPS Diluted | 73.71% | 70.75% | 50.09% | 21.90% | -4.12% |
| Normalized Diluted EPS | 74.06% | 70.97% | 52.39% | 24.05% | -1.72% |
| Average Basic Shares Outstanding | 39.15% | 24.16% | 14.00% | 5.39% | 3.98% |
| Average Diluted Shares Outstanding | 39.15% | 24.16% | 14.00% | 5.39% | 3.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |